NEW DELHI: India’s Sovereign Pharma said it has dispatched the first batch of the experimental COVID-19 treatment remdesivir for drugmaker Cipla.
Sovereign, which is manufacturing and packaging Cipla’s remdesivir version, added that it can supply 50,000 to 95,000 vials per month of the injectable.
Cipla had said it would price a 100 mg vial of its remdesivir, Cipremi, at less than ₹5,000.
Privately held Hetero Labs Ltd and drugmaker Mylan NV have also got regulatory approval in India for their generic versions of remdesivir.
Hetero will price its version, Covifor, at 5,400 rupees per 100 mg vial, while Mylan will price Desrem at 4,800 rupees. Hetero has said it will supply 20,000 vials of the drug to hospitals in India.
Earlier, Gilead has licensed remdesivir to 5 drugmakers in India and Pakistan who can make the experimental COVID-19 drug for distribution in 127 countries.
The companies are Cipla, Hetero Labs, Jubilant Lifesciences and Mylan in India and Pakistan’s Ferozsons Laboratories.
The licences are royalty-free until WHO declares the end of the pandemic or until another COVID-19 drug or vaccine is approved.